Abstract
We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone. The remarkable clinical improvement in joint symptoms within 24 h and in glycemic control during a 6-month period gives anakinra a potential therapeutic role in the management of gout and type 2 diabetes. When anakinra was discontinued, a gout attack occurred within 3-25 days in all three patients. The contribution of anakinra in the treatment of such syndromes is encouraging, but requires further studies to establish its long-term efficacy.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Allopurinol / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antirheumatic Agents / therapeutic use*
-
Blood Glucose / metabolism
-
Carbamates / therapeutic use
-
Colchicine / therapeutic use
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / metabolism
-
Febuxostat / therapeutic use
-
Glycated Hemoglobin / metabolism
-
Gout / complications
-
Gout / drug therapy*
-
Gout Suppressants / therapeutic use*
-
Humans
-
Hyperuricemia / blood
-
Hyperuricemia / complications
-
Hyperuricemia / drug therapy*
-
Hypoglycemic Agents / therapeutic use*
-
Insulin / therapeutic use
-
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
-
Metformin / therapeutic use
-
Middle Aged
-
Piperidines / therapeutic use
-
Treatment Outcome
-
Uric Acid / blood
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antirheumatic Agents
-
Blood Glucose
-
Carbamates
-
Glycated Hemoglobin A
-
Gout Suppressants
-
Hypoglycemic Agents
-
Insulin
-
Interleukin 1 Receptor Antagonist Protein
-
Piperidines
-
hemoglobin A1c protein, human
-
Febuxostat
-
Uric Acid
-
Allopurinol
-
repaglinide
-
Metformin
-
Colchicine